Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.

Zhu Q, Yu Z, Kabashima T, Yin S, Dragusha S, El-Mahdy AF, Ejupi V, Shibata T, Kai M.

Sci Rep. 2015 May 19;5:10323. doi: 10.1038/srep10323.

2.

Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

Truong WR, Schafer JJ, Short WR.

P T. 2015 Jan;40(1):44-55.

3.

Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.

Katusiime C, Ocama P, Kambugu A.

Afr Health Sci. 2014 Sep;14(3):679-81. doi: 10.4314/ahs.v14i3.25. Review.

4.

Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.

Singh K, Flores JA, Kirby KA, Neogi U, Sonnerborg A, Hachiya A, Das K, Arnold E, McArthur C, Parniak M, Sarafianos SG.

Viruses. 2014 Sep 24;6(9):3535-62. doi: 10.3390/v6093535. Review.

5.

Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching.

Luo R, Piovoso MJ, Zurakowski R.

Proc Am Control Conf. 2010;2010:5155-5160.

6.

Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, Sirisanthana T, Kantipong P, Lee C, Kamarulzaman A, Mustafa M, Ditangco R, Merati T, Ratanasuwan W, Singtoroj T, Kantor R.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):74-9. doi: 10.1097/QAI.0000000000000108.

7.

Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.

Younan PM, Polacino P, Kowalski JP, Peterson CW, Maurice NJ, Williams NP, Ho O, Trobridge GD, Von Laer D, Prlic M, Beard BC, DeRosa S, Hu SL, Kiem HP.

Blood. 2013 Jul 11;122(2):179-87. doi: 10.1182/blood-2013-01-482224. Epub 2013 May 29.

8.

HIV Drug-Resistant Patient Information Management, Analysis, and Interpretation.

Singh Y, Mars M.

JMIR Res Protoc. 2012 Jun 7;1(1):e3. doi: 10.2196/resprot.1930.

9.

Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008.

Buchacz K, Baker R, Ward DJ, Palella FJ, Chmiel JS, Young B, Yangco BG, Novak RM, Brooks JT.

AIDS Res Treat. 2012;2012:230290. doi: 10.1155/2012/230290. Epub 2012 Mar 14.

10.

HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Neuman MG, Schneider M, Nanau RM, Parry C.

Int J Hepatol. 2012;2012:760706. doi: 10.1155/2012/760706. Epub 2012 Mar 11.

11.

A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.

Wandeler G, Keiser O, Hirschel B, G√ľnthard HF, Bernasconi E, Battegay M, Clerc O, Vernazza PL, Furrer H; Swiss HIV Cohort Study.

PLoS One. 2011;6(12):e27903. doi: 10.1371/journal.pone.0027903. Epub 2011 Dec 20.

12.

Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.

Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J, Yang C.

PLoS One. 2011;6(11):e28184. doi: 10.1371/journal.pone.0028184. Epub 2011 Nov 23.

13.

Toward targeting RNA structure: branched peptides as cell-permeable ligands to TAR RNA.

Bryson DI, Zhang W, McLendon PM, Reineke TM, Santos WL.

ACS Chem Biol. 2012 Jan 20;7(1):210-7. doi: 10.1021/cb200181v. Epub 2011 Oct 28.

14.

The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

Schafer JJ, Ravi S, Rowland EV, Shenoda G, Leon N.

P T. 2011 Jun;36(6):346-64. No abstract available.

15.

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Wang D, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, Cai F, Perelson AS, Gao F.

J Virol. 2011 Jul;85(13):6403-15. doi: 10.1128/JVI.02389-10. Epub 2011 Apr 13.

16.

Genetic barriers to resistance and impact on clinical response.

Luber AD.

J Int AIDS Soc. 2005 Jul 7;7(3):69. doi: 10.1186/1758-2652-7-3-69.

17.

Information management to enable personalized medicine: stakeholder roles in building clinical decision support.

Downing GJ, Boyle SN, Brinner KM, Osheroff JA.

BMC Med Inform Decis Mak. 2009 Oct 8;9:44. doi: 10.1186/1472-6947-9-44.

18.

Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

May S, Gamst A, Haubrich R, Benson C, Smith DM.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):194-201. doi: 10.1097/QAI.0b013e3181ba37a7.

19.

Predictive value of HIV-1 genotypic resistance test interpretation algorithms.

Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW.

J Infect Dis. 2009 Aug 1;200(3):453-63. doi: 10.1086/600073.

20.

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.

Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, Sayer D, Smith J, Dax EM, Law M; TAQAS Laboratory Network.

J Virol Methods. 2009 Aug;159(2):185-93. doi: 10.1016/j.jviromet.2009.03.016. Epub 2009 Mar 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk